Background-Although modern combination antiretroviral therapy (cART) regimens are better tolerated and less complex than earlier treatments, regimen modification or discontinuation remains a concern.
Methods The HIV Outpatient Study
The HOPS is an ongoing, prospective observational cohort study that has continuously recruited and followed HIV-infected patients since 1993. In the timeframe of this analysis, study sites included 12 clinics (6 university, 4 public, and 2 private) in eight U.S. cities, with a total enrollment of over 10,000 patients (approximately 2,500 actively seen in any given year). We analyzed data from HOPS participants seen at clinic sites located in: Tampa, FL (2 sites); Washington, DC; Denver, CO (2 sites); Chicago, IL (2 sites); Portland, OR; Walnut Creek, CA; Oakland, CA; Stony Brook, NY; and Philadelphia, PA. HOPS clinicians have extensive experience treating HIV-infected patients. The study protocol is approved and renewed annually by each participating institution's ethical review board. All study participants provide written, informed consent.
Trained staff at each site abstract outpatient medical record information, electronically enter these data, and submit them to the data management center to be compiled centrally, reviewed and edited before analysis. Abstracted information includes demographic characteristics and risk factors for HIV infection; diagnoses; prescribed medications, including dose and duration; laboratory values, including CD4+ cell counts and plasma HIV RNA levels (viral loads); causes of mortality and hospitalizations; and primary medical care payment source.
Study population
We limited analysis to patients who were ART-naïve before starting their first cART regimen, had complete documentation of ART history, and initiated either first or second cART regimen during one of four calendar periods: 1996-1999, 2000-2003, 2004-2007 or 2008-2011 while under the observation in the HOPS. We used the HOPS dataset updated as of 31 December 2013; data from patients receiving ongoing cART regimens were censored for analysis on 30 June 2013 to allow for lag in data entry. In this way, we ensured that patients who initiated cART through the end of 2011 had an opportunity to be observed while receiving cART for at least one year.
Definitions of predictor and outcome variables
For this analysis, we defined cART as three or more antiretroviral drugs. "Baseline" was defined as the date of first or second cART regimen initiation, as appropriate. Baseline viral load and CD4+ cell counts were measurements obtained closest to cART regimen start, and within 183 days before and up to 7 days after regimen start. We analyzed two outcomes: cART regimen modification and virologic suppression after baseline. Regimen modification was defined as a change in at least one antiretroviral drug in the regimen not including dose changes, switches to a fixed dose combination of the same drugs, or switches between lamivudine and emtricitabine, and could include regimen discontinuation (temporary or permanent) defined as discontinuation of all drugs in the regimen for at least 14 days. Since discontinuations accounted for a minority of such events, we henceforth refer to regimen modification as encompassing modification/discontinuation. We characterized first cART regimens by whether they contained non-nucleoside reverse transcriptase inhibitors (NNRTIs), low-dose ritonavir (RTV)-boosted or non-boosted PIs, or integrase or entry inhibitors, creating exclusive categories in the following order: NNRTI, integrase or entry inhibitor, RTV-boosted PI, and non-boosted PI. Virologic suppression was defined as achieving an undetectable plasma HIV viral load (per manufacturer's assay-specific lower limit of detection cut-off), and calculated for HIV viral load tests with lower limit of detection < 400 copies/mL (n=1,652 or 15% of viral load measurements using assays with a lower limit of detection of 400 copies/mL or higher in earlier calendar years were excluded from analysis).
Statistical analyses
To compare distinct subgroups of patients across the four calendar periods, we used a likelihood ratio chi-square or a Jonckheere-Terpstra trend test. For treatment-naïve persons who initiated first cART regimen during one of the calendar periods (1996-1999, 2000-2003, 2004-2007, and 2008-2011) , we used Kaplan-Meier survival curves that incorporate the censoring to estimate time to regimen modification and time to virologic suppression, and log-rank tests to compare curves among calendar periods. We similarly analyzed cART treatment-experienced persons who initiated second cART regimen during these periods. Because some patients were included in both the first and second cART regimen analyses (see Results for details), outcomes for first and second regimen durations for these patients are correlated; thus, first versus second regimen durations for the same calendar period were not directly compared statistically in our analysis. Furthermore, for treatment-naïve patients who initiated first cART regimens, we used multivariable proportional hazards regression models to identify factors independently associated with regimen modification and with virologic suppression for regimens initiated in each calendar period. We adjusted for sociodemographic variables (e.g., sex, race/ethnicity, insurance) and HIV-related measures (e.g., baseline CD4+ cell count, class of cART regimen) that we considered as potentially associated with achieving a more durable response and virologic suppression while on cART. All variables were included in each of the models regardless of significance, with the exception of variables that were not relevant in the time period of interest, i.e., integrase/ entry inhibitor use prior to 2008. In the analysis of time to virologic suppression, for patients with missing baseline viral load values we used the Markov chain Monte Carlo method for multiple imputations 11, 12 to estimate baseline viral loads using demographic and baseline CD4+ cell count data. This process involves using information from patients with known baseline viral loads to estimate baseline viral loads for patients with unknown information. Assuming that patients with similar baseline CD4+ cell counts and demographic characteristics are also likely to have similar baseline viral loads, we created new data sets that included baseline viral load information statistically "imputed" for patients previously missing these data. Five imputations, the default quantity, were created by the statistical software. The results of the five analyses were then combined to obtain a measure of the error produced by this imputation process. Statistical analyses were done using SAS v9.3 (Cary, NC).
Results

Demographic and clinical characteristics
Among 8,910 HOPS patients with ≥2 visits during 1996-2011, we identified 1,734 patients who met inclusion criteria for first cART regimen analyses; we excluded 6,827 patients who were ART-experienced at start of HOPS observation or before 1996, 204 patients with an incomplete ART history recorded, and 145 patients who initiated cART after 2011 (i.e., outside of the timeframe for this analysis).
In a separate selection process, among 3,068 HOPS patients with ≥2 visits during 1996-2011, complete ART histories, and whose only antiretroviral experience was a single cART regimen (initiated before or after start of HOPS observation), we identified 897 patients meeting inclusion criteria for second cART regimen analyses; we excluded 2,104 patients who did not start a second cART regimen during HOPS observation, and 67 who started second cART after 2011 (i.e., outside of the timeframe for this analysis). Table 1 . Of the 1,734 and 897 who initiated first and second cART regimens, there were 212 (12.2%) and 30 (3.3%), respectively, with no pre-cART viral load recorded whose values were therefore imputed.
Among first cART initiators, median age was 38 years (interquartile range [IQR] 31-45), and the majority were male (77%), many were white non-Hispanic/Latino (44%), in the risk group of men who have sex with men (MSM) (53%), and had private insurance (53%). Among patients who initiated second cART, median age was 40 years (IQR 34-47), and the majority were male (82%), white non-Hispanic/Latino (50%), MSM (59%), and had private insurance (66%). Most demographic characteristics did significantly change over time among patients who initiated first cART: median age increased slightly, the percentage of black non-Hispanic/Latinos and Hispanic/Latinos increased, and the percentage who reported a history of injection drug use (IDU) or who received cART regimens dosed more often than once daily decreased across the calendar periods; for second cART, median age increased, and the proportion who reported a history of injection drug use (IDU) or who received cART regimens dosed more often than once daily decreased across the calendar periods (see Table 1 ). These demographic trends were comparable to those observed across these calendar periods in the overall HOPS cohort (data not shown). 13, 14 Among first cART initiators, median baseline plasma viral load was 4.8 log 10 copies/mL (IQR 4.2-5.3) and median baseline CD4+ cell count was 260 cells/mm 3 (IQR 102-407); median baseline viral load decreased among patients initiating cART over the four calendar periods, ranging from 4.7 to 4.5 log 10 copies/mL (p=0.002 for trend), and median CD4+ cell count increased over time from 262 to 318 cells/mm3 (p=0.001 for trend). For second cART initiators, median baseline plasma viral load was 2.0 log 10 copies/mL (IQR 1.4-3.5) and median baseline CD4+ cell count was 397 cells/mm 3 (IQR 219-639); median baseline viral load was progressively lower over the four calendar periods, ranging from 3.0 to 1.7 log 10 copies/mL, and median CD4+ cell count increased over time from 294 to 480 cells/mm 3 (both p<0.001).
The most commonly prescribed first cART regimens included a non-boosted PI in calendar period 1996-1999, an NNRTI cART in 2000-2003 and 2008-2011, and a RTV-boosted-PI in 2004-2007 (Table 1) . Second cART regimen types were most likely to include a nonboosted PI in 1996-1999, and an NNRTI in 2000-2003 and 2004-2007 , and an integrase or entry inhibitor in 2008-2011. Over time, the daily dosing frequency of first and second cART diminished; for example, 50% of first cART regimens were dosed three times daily in 1996-1999 compared with less than 1% in 2008-2011. First and second cART regimens were more likely to involve once daily dosing in more recent periods (p<0.001). Among regimens prescribed during 2008-2011, 72% of first cART and 63% of second cART were once-daily regimens.
cART regimen duration and success
Combination ART regimens were modified for 1,231 (71%) of 1,734 patients initiating a first cART regimen and 641 (71%) of 897 patients initiating a second cART regimen; observation time was censored for the remaining patients who continued cART regimens past the end of the follow-up period ( Table 2 ). These regimen modifications included 318 regimen discontinuations (of at least 2 weeks) for first cART regimens and 109 regimen discontinuations for second cART regimens. Estimated median durations of first and second cART regimens were 1.6 (95% confidence interval [CI] 1.4-1.7) and 1.6 (95% CI 1.4-1.8) years, respectively, and each increased significantly across calendar periods (Figures 1a and 1b, p<0.001). Median first cART regimen durations increased over calendar time; they were 1.0 (95% CI 0.8-1.1), 1.1 (95% CI 1.0-1.5), 2.1 (95% CI 1.6-2.6), and 4.6 (3.8indeterminate upper confidence limit) years for regimens initiated in 1996-1999, 2000-2003, 2004-2007, and 2008-2011, respectively . The percentage of patients remaining on first cART regimens at 24 months after initiation was 45% overall; this percentage was 32%, 38%, 51%, and 63%, respectively, for patients starting first cART during each of the four calendar periods ( Table 2 ). Median second cART regimen durations also increased over calendar time; they were 0.9 (95% CI 0.7-1.1), 1.2 (95% CI 0.9-1.3), 2.8 (95% CI 2.1-4.7) and 3.9 (95% CI 2.3-indeterminate upper confidence limit) years, respectively. The percentage of patients remaining on second cART regimens at 24 months after initiation was 43% overall, and 25%, 31%, 57%, and 58%, respectively, for the four calendar periods ( Table 2 ).
The percentage of patients who achieved virologic suppression within 6 months of cART initiation significantly increased over the four calendar periods, from 65% to 81% for first cART, and from 63% to 80% for second cART (Figures 1c and 1d , p<0.001 for each). Among patients with baseline HIV viral loads >1,000 copies/mL, the percentage who achieved virologic suppression within 6 months of regimen initiation also increased over 
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Author Manuscript time, from 41% to 64% on first cART (p<0.001) and from 33% to 67% on the second cART (p<0.001).
Factors associated with first cART regimen duration and success
For first cART regimens initiated during the first calendar period (1996) (1997) (1998) (1999) 
Discussion
In the HOPS, median durations of first and second cART regimens have increased significantly over time during the 15-year period represented in this analysis, corroborating reports from earlier cohorts that included regimens initiated up to 2009. [5] [6] [7] 15, 16 These changes in cART regimen duration were temporally coincident with the availability of more tolerable, less complex cART regimens that required less frequent dosing. While median regimen durations were only approximately one year for both first and second cART among HOPS patients who initiated these regimens during the first two calendar periods of our study (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) , they exceeded a median of two years in the latter two calendar periods (2004-2011), and approached 5 years for first cART in the most recent calendar period ending in 2011. For the earlier time periods, first cART regimen durations were similar to those recently reported for other U.S. cohorts 4-6 but, with the 4.6 year median duration of first cART that we observed during the most recent calendar period (2008-2011), exceeded cART regimen durations recently reported from the Multicenter AIDS Cohort Study. 7 As the duration of the first and second cART regimens increased over time, the percentage of persons who achieved viral suppression within 6 months of regimen initiation likewise increased markedly over time, corroborating randomized clinical trial-generated data that report improved potency, tolerability, and adherence associated with more contemporary regimens. 17 Understanding cART regimen characteristics that were associated with increased rates of first cART modification and viral non-suppression in the most recent calendar period may inform regimen selection for contemporary patients. As in reports from other cohorts, 5 we found that twice or more daily dosing was associated with increased rates of cART regimen modification and decreased rates of achieving viral suppression. Once-daily cART regimens are preferred in current HIV treatment guidelines for initial therapy. 17 Furthermore, our findings concur with those from other cohorts suggesting that the use of NNRTI-containing regimens has been associated with decreased rates of cART modification compared with the use of some RTV-boosted PI-containing regimens. 5, 7, 15, 18 We found that black non-Hispanic race/ethnicity was a demographic associated with discontinuing or modifying cART for regimens initiated during 2008-2011. This could reflect lower regimen adherence among this patient group [19] [20] [21] [22] or other ART-related factors such as financial cost, tolerability, or toxicity. Notably, during this same time, black non-Hispanic race/ethnicity was not associated with diminished likelihood of achieving viral suppression.
There are important methodological issues relevant to the interpretation of our results. Earlier analysis from the HOPS cohort demonstrated that first cART regimens tend to be more durable than subsequent ones, 2 which is consistent with clinical experience. However, no such trend emerged in our present multi-year study. We could not perform direct statistical comparisons of first and second cART regimen durations because many patients included the analyses of first cART were not included in the analyses of second cART and, by definition, observation on second cART follows observation on first cART, resulting in correlated data for some patients. Our analysis nonetheless indicates that effective and tolerable cART treatment options exist for treatment-experienced patients. In the most contemporary time period evaluated, the likelihood of achieving treatment success (i.e., remaining on durable, virally suppressive and tolerable cART) did not appear to differ substantially for cART-treated patients compared with patients newly initiating cART.
The findings from our study are subject to additional limitations and caveats. First, we analyzed data abstracted from medical records of patients in routine HIV care; specific reasons for regimen modification or discontinuation were not uniformly charted or were missing for many patients, and cART adherence data, which may have impacted regimen duration, were not systematically gathered. Second, because of patient aging and other demographic shifts occuring over time among HOPS participants initiating cART, it is possible that changes in cART regimen durations could be influenced by these shifts and were not due solely to improvements in cART potency, tolerability and regimen dosing during the timeframe of the study. Third, because we assessed percentages of patients who achieved viral suppression based on prevailing lower thresholds of detection for viral load, which were relatively higher in earlier calendar years, our findings related to temporal improvements in virologic suppression may be conservative. Fourth, despite the fact that the HOPS includes a large number of patients drawn from multiple and diverse HIV specialty clinics, our findings may not be generalizable to HIV-infected persons receiving cART in other care settings in the U.S. A recent analysis comparing characteristics of HOPS patients to all HIV-infected persons included in the national HIV Surveillance System revealed that HOPS patients tended to be older, and more frequently non-Hispanic white, non-injection drug using, and diagnosed with AIDS. 23 In summary, among HOPS participants the duration of first and second cART regimens has increased substantially over time, particularly in the most recent (2008-2011) calendar period studied. Likewise, time to achievement of viral suppression after cART initiation decreased over time for both first and second cART recipients. Our findings likely reflect the benefits of newer cART regimens in terms of improved efficacy, tolerability, and simplicity (with once-daily dosing for many regimens). We identified a patient group for whom regimen modification was more likely during the most recent calendar period (i.e., persons of black non-Hispanic/Latino race/ethnicity), suggesting that interventions aimed at improving ART adherence and tolerability in this patient group are justified in order to extend cART regimen longevity. Trends in cART regimen use, regimen durability, and reasons for regimen modification warrant ongoing surveillance in order to better inform regimen selection for persons receiving initial and subsequent cART. Table 1 Baseline demographic and clinical characteristics of patients initiating first and second cART, the HIV Outpatient Study, 1996-2011. Table 2 First and second cART regimen modifications and discontinuations by calendar period of regimen initiation, the HIV Outpatient Study, 1996-2011. Table 3 Multivariable Cox proportional hazards regression models by calendar period of cART initiation for factors associated with time to first cART regimen modification/discontinuation, the HIV Outpatient Study, 1996-2011 (N = 1,734; n = 1,231 [71%] observed to discontinue first ART regimen during follow-up period). Baseline characteristics listed in the table were included in all models except where noted. 
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